On November 4 Shi Yigong (Dean of the School of Life Sciences and Executive Vice Dean of the School of Medicine of Tsinghua University), Ma Jun (Director of Overseas R&D Management Office of Tsinghua University) and Johan Van Hoof (Global Therapeutic Area Head, Infectious diseases & Vaccines of Johnson & Johnson Pharmaceutical R&D), jointly signed the agreement on the “Tsinghua-Janssen Contagious Disease Research Cooperation Project”.
The project will last 5 years and has the aim to promote research into cures for contagious diseases, thereby meeting medical needs for public health in China and the world. As part of this project, Tsinghua University and Xi’an Janssen will establish a research network to focus on studies into a wide range of contagious diseases including pulmonary tuberculosis, malaria, diseases caused by HIV, HBV, Dengue fever virus, HPV, EBV, HCMV, HSV, Norwalk virus, human coronary virus, adenovirus, EV, chikungunya virus, hemorrhagic fever virus, RSV, human rhino virus and other human bacterial pathogens.
Xi’an Janssen was established in 1985. It is a large modern pharmaceutical corporation, jointly founded by Belgium Janssen Pharmaceutical Ltd., which is a wholly-owned subsidiary of Johnson & Johnson, Shaanxi Pharmaceutical Corporation, Shaanxi Hanjiang Pharmaceutical Co. Ltd., China Pharmaceutical Industrial Corporation, and China Pharmaceutical Foreign Trade Corporation. Over the past 25 years Xi’an Janssen has been devoted to the development of close cooperation with local medical experts in areas of pharmaceutical innovation and clinical treatment.
